The deal expands BD’s presence into the emerging affordable personal flow cytometer space, and also expands the use of flow cytometry technology.
BD Biosciences president William Rhodes said the acquisition of Accuri Cytometers broadens BD’s offerings for life scientists by making flow cytometry more accessible to a wider audience of scientists and clinicians.
"This includes researchers in scientific disciplines that have not traditionally used flow cytometry, such as environmental sciences, microbiology and marine biology," Rhodes added.